Tiotropium as a First-Line Maintenance Therapy for COPD (UPLIFT)

Tiotropium (LAMA) was approved for COPD, but its effect on disease progression (FEV1 decline) and mortality was unknown. UPLIFT was the largest and longest COPD bronchodilator trial at the time.

Multicenter RCT (490 centers, 37 countries, n=5,993) comparing tiotropium 18 mcg/day vs. placebo over 4 years in COPD patients (FEV1/FVC <0.70, FEV1 ≤70% predicted).

Tiotropium did not significantly reduce the rate of FEV1 decline (primary endpoint). However, it significantly improved FEV1, quality of life (SGRQ), reduced exacerbations (14% reduction), and reduced hospitalizations. Mortality was numerically lower but not statistically significant.

Tiotropium (LAMA) is a cornerstone of COPD maintenance therapy. It improves symptoms, reduces exacerbations, and improves quality of life. LAMAs are recommended as first-line therapy in GOLD group B and above.

Did not meet primary endpoint (FEV1 decline). Patients could use other bronchodilators — contamination of the control arm.